Evidity Health Capital is a late-stage venture capital and growth equity firm focused on private medical technology companies, including medical devices, in vitro diagnostics, and disruptive digital health. Founded in 2014 as Canepa Healthcare, the firm invests in companies with commercialized products that have achieved U.S. regulatory clearance and need growth capital to scale. The firm rebranded to Evidity Health Capital in late 2019.
36% of their portfolio is in Healthcare. Their most common stage is series-d (64% of deals). Average disclosed round size is $68.2M (across 11 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series D
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 GT Medical Technologies | Series D | $53M | Jul 2025 |
| GT Medical Technologies | Series D | $37M | Jan 2025 |
| GGT Medical Technologies, Inc. | Series D | $37M | Jan 2025 |
| AAugmedics | Series D | $82.5M | Jan 2023 |
| PPrelude Corporation (PreludeDx) | Growth | $20M | Mar 2022 |
 Magnolia Medical Technologies | Growth | $46M | Feb 2022 |
 Akili Interactive Labs, Inc. | Series D | $110M | May 2021 |
| AAkili, Inc. | Series D | $110.0M | May 2021 |
| AAkili, Inc. | Series D | $110M | Jan 2021 |
| CCardiva Medical, Inc. | Unknown | $45M | Jul 2020 |
| GGT Medical Technologies, Inc. | Series E | $100M | — |
Top Co-Investors
Gilde Healthcare4 shared
Accelmed Partners3 shared
MedTech Venture Partners3 shared
New Leaf Venture Partners3 shared
QUAD Investment Management3 shared
Fearless Fund3 shared
M Ventures3 shared
Baillie Gifford3 shared
Neuberger Berman3 shared
Amgen Ventures3 shared
Polaris Partners3 shared
VMG Partners2 shared
Mirae Asset2 shared
JAZZ Venture Partners2 shared
SightLine Partners1 shared
RTW Investments, LP1 shared
HealthQuest Capital1 shared
Sectoral Asset Management1 shared
W Health Ventures1 shared
Last updated: 8 September 2026